Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Merz Pharmaceuticals, LLC currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are concentrated in 1 distinct art unit, suggesting a specific technical focus for the pending applications. The prosecution involves 2 distinct examiners, meaning each pending action is being reviewed by a different person.
The busiest examiner, HAGHIGHATIAN, MINA, is responsible for 1 busiest_examiner_pending action. This represents 1 of the 2 total pending office actions for the company. Although the 2 pending actions are assigned to 2 distinct examiners, they both fall within the same 1 distinct art unit, which provides the examination environment.
With 2 pending office actions and 2 distinct examiners, the company must manage 2 separate dialogues within the Biotechnology & Pharmaceuticals sector. The 1 distinct art unit involved means that both examiners are working within the same administrative group. This structure requires the company to address the individual preferences of 2 distinct examiners while operating under the standards of 1 art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17892436 | SURFACTANT FORMULATIONS FOR INHALATION | HELM, CARALYNNE E | 98d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17892436 | SURFACTANT FORMULATIONS FOR INHALATION | HELM, CARALYNNE E | 98d overdue |
| 18989671 | Surfactant Formulations for Inhalation | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18989671 | Surfactant Formulations for Inhalation | HAGHIGHATIAN, MINA | — | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2024 |
| 17892436 | SURFACTANT FORMULATIONS FOR INHALATION | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | 98d overdue | Pending | Aug 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial